Ophthotech Corp (OPHT) Receives Average Recommendation of “Hold” from Analysts
Ophthotech Corp (NASDAQ:OPHT) has received a consensus rating of “Hold” from the four brokerages that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $4.00.
Several analysts have recently commented on OPHT shares. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. Zacks Investment Research downgraded shares of Ophthotech from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine downgraded shares of Ophthotech from a “buy” rating to a “hold” rating in a report on Thursday, March 1st.
In other Ophthotech news, CEO Glenn Sblendorio sold 8,089 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total value of $25,803.91. Following the completion of the sale, the chief executive officer now directly owns 44,584 shares of the company’s stock, valued at approximately $142,222.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider David R. Guyer sold 16,520 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $52,698.80. Following the completion of the sale, the insider now directly owns 50,494 shares of the company’s stock, valued at $161,075.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,971 shares of company stock valued at $111,481. 2.00% of the stock is owned by corporate insiders.
Shares of Ophthotech (NASDAQ:OPHT) traded up $0.02 during trading on Friday, hitting $2.99. 300,594 shares of the stock traded hands, compared to its average volume of 261,502. The stock has a market cap of $108.09, a PE ratio of 0.94 and a beta of 1.42. Ophthotech has a 1-year low of $2.24 and a 1-year high of $3.80.
Ophthotech (NASDAQ:OPHT) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.32. Ophthotech had a net margin of 26.69% and a negative return on equity of 230.07%. During the same quarter in the previous year, the firm posted ($1.86) EPS. equities research analysts expect that Ophthotech will post -1.71 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Ophthotech Corp (OPHT) Receives Average Recommendation of “Hold” from Analysts” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/03/11/ophthotech-corp-opht-receives-average-recommendation-of-hold-from-analysts.html.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.